Wire · operational-macro
BioNTech to pay $205M for FDA priority review voucher
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 November 2026 · Fusion42 review
BioNTech will acquire a US FDA priority review voucher from Scholar Rock for $205 million to expedite the regulatory review of a late-stage oncology treatment in its pipeline. The transaction is subject to customary closing conditions including antitrust clearance.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 10 Nov 2026 and 12 Nov 2026.
◆ ◆ The Wire takeaway
Priority review vouchers can speed cancer drug approvals, opening a regulatory fast lane for you if your biotech startup targets oncology. This payment signals a direct route to accelerate FDA approval timelines that you can now aim to leverage.
◆ Coverage
3 sources · first reported 10 Nov 2026 · latest 12 Nov 2026
◆ Related on Wire
◆ Topics